Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension
Author:
Affiliation:
1. Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA
Funder
National Eye Institute
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1293654
Reference72 articles.
1. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
2. The Changing Face of Primary Open-Angle Glaucoma in the United States: Demographic and Geographic Changes From 2011 to 2050
3. Burden of Undetected and Untreated Glaucoma in the United States
4. The Pathophysiology and Treatment of Glaucoma
Cited by 47 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study;PLOS ONE;2024-08-22
2. A Narrative Review of Pharmacotherapy of Glaucoma;Future Pharmacology;2024-05-27
3. Effect of Latanoprostene Bunod on the Permeability of Trabecular Meshwork Cells;Journal of the Korean Ophthalmological Society;2024-02-15
4. Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%;Journal of Current Glaucoma Practice;2024-01-17
5. Simulation of gravity- and pump-driven perfusion techniques for measuring outflow facility of ex vivo and in vivo eyes;PLOS ONE;2023-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3